High
0.905
Open
0.890
VWAP
--
Vol
315.23K
Mkt Cap
28.14M
Low
0.8349
Amount
--
EV/EBITDA(TTM)
--
Total Shares
22.22M
EV
31.22M
EV/OCF(TTM)
--
P/S(TTM)
12.24
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
500.00K
+125.75%
--
--
2.00M
+260.42%
--
--
2.45M
+321.27%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Femasys Inc. (FEMY) for FY2025, with the revenue forecasts being adjusted by 15.67% over the past three months. During the same period, the stock price has changed by -26.06%.
Revenue Estimates for FY2025
Revise Upward

+15.67%
In Past 3 Month
Stock Price
Go Down

-26.06%
In Past 3 Month
3 Analyst Rating

709.16% Upside
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 7.00 USD with a low forecast of 3.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

709.16% Upside
Current: 0.865

Low
3.00
Averages
7.00
High
12.00

709.16% Upside
Current: 0.865

Low
3.00
Averages
7.00
High
12.00
JonesResearch
Buy
downgrade
$10 -> $6
2025-05-13
Reason
JonesResearch
Price Target
$10 -> $6
2025-05-13
downgrade
Buy
Reason
JonesResearch lowered the firm's price target on Femasys to $6 from $10 and keeps a Buy rating on the shares. The company reported Q1 earnings with no major updates to catalysts or its cash runway, the analyst tells investors in a research note. The firm remains positive on Femasys, but cut its price target to reflect the delayed launch of FemaSeed and an increase in share count from potential financing in 2025.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$15
2025-03-28
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$15
2025-03-28
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Maintains
$12 → $15
2025-03-19
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12 → $15
2025-03-19
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-18
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-03-13
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-03-13
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$12
2025-02-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$12
2025-02-26
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Femasys Inc (FEMY.O) is -1.64, compared to its 5-year average forward P/E of -2.23. For a more detailed relative valuation and DCF analysis to assess Femasys Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-2.23
Current PE
-1.64
Overvalued PE
-0.54
Undervalued PE
-3.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
15.50
Current PS
3.71
Overvalued PS
34.63
Undervalued PS
-3.64
Financials
Annual
Quarterly
FY2025Q1
YoY :
+25.86%
341.26K
Total Revenue
FY2025Q1
YoY :
+57.70%
-5.46M
Operating Profit
FY2025Q1
YoY :
+63.82%
-5.90M
Net Income after Tax
FY2025Q1
YoY :
+35.29%
-0.23
EPS - Diluted
FY2025Q1
YoY :
+4.37%
-4.86M
Free Cash Flow
FY2025Q1
YoY :
-0.75%
40.77
Gross Profit Margin - %
FY2025Q1
YoY :
-5.75%
-1.21K
FCF Margin - %
FY2025Q1
YoY :
+30.16%
-1.73K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
FEMY News & Events
Events Timeline
2025-07-01 (ET)
2025-07-01
09:06:54
Femasys announces achievement of regulatory approvals in Australia, NZ

2025-06-25 (ET)
2025-06-25
09:09:51
Femasys announces milestone with European approval of FemBloc

2025-06-17 (ET)
2025-06-17
09:10:44
Femasys appoints Nicholas as CCO

Sign Up For More Events
Sign Up For More Events
News
9.0
07-01NewsfilterFemasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
4.0
06-25BenzingaHC Wainwright & Co. Reiterates Buy on Femasys, Maintains $12 Price Target
5.0
06-17NewsfilterFemasys Names New Chief Commercial Officer to Drive Execution and Global Growth
Sign Up For More News
People Also Watch

TRT
Trio-Tech International
5.335
USD
-1.02%

ENLV
Enlivex Therapeutics Ltd
1.260
USD
+12.30%

CODX
Co-Diagnostics Inc
0.278
USD
-1.07%

LVTX
LAVA Therapeutics NV
1.520
USD
+6.29%

NRSN
Neurosense Therapeutics Ltd
2.030
USD
0.00%

LGVN
Longeveron Inc
1.640
USD
-1.80%

MXC
Mexco Energy Corp
8.200
USD
+2.12%

UTSI
UTStarcom Holdings Corp
2.550
USD
+1.59%

KFFB
Kentucky First Federal Bancorp
3.250
USD
-0.03%
FAQ

What is Femasys Inc (FEMY) stock price today?
The current price of FEMY is 0.8651 USD — it has decreased -3.89 % in the last trading day.

What is Femasys Inc (FEMY)'s business?

What is the price predicton of FEMY Stock?

What is Femasys Inc (FEMY)'s revenue for the last quarter?

What is Femasys Inc (FEMY)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Femasys Inc (FEMY)'s fundamentals?

How many employees does Femasys Inc (FEMY). have?
